Zevra Therapeutics, INC 10-Q quarterly reports

Zevra Therapeutics announced a substantial increase in revenue for the second quarter of 2026, driven by MIPLYFFA sales and expanded access programs, while also detailing debt repayment and ongoing clinical trial progress.

Zevra Therapeutics reports Q1 2026 net income of $37.9 million, bolstered by a $43.3 million gain from the sale of its SDX portfolio assets.

Zevra Therapeutics reported a significant increase in revenue and a swing to net income for the nine months ended September 30, 2025, driven by strong MIPLYFFA sales and a $148.3 million PRV sale, despite an impairment charge for OLPRUVA.

Zevra Therapeutics posted a significant net income increase in Q2 2025, driven by a $148.3 million Priority Review Voucher sale, despite an impairment charge on its OLPRUVA asset and ongoing operational losses.

Zevra Therapeutics completes the sale of its Priority Review Voucher for $150 million and reports a net loss of $3.1 million for Q1 2025, driven by increased product revenue and strategic cost management.

Zevra Therapeutics reports a net loss of $33.2 million for the third quarter of 2024, alongside updates on its commercial and clinical programs.

Zevra Therapeutics reports a net loss of $19.9 million for the second quarter of 2024, alongside updates on its pipeline and commercial activities.

Zevra Therapeutics reports a net loss of $16.6 million for the first quarter of 2024, alongside revenue of $3.4 million, and provides updates on its commercial and clinical programs.